FDA Webview Site FDA Review Site FDA Updater Site
header.gif
Username:
Password:
 

human drugs
animal drugs
biologics
eirs 483s
medical devices
marketing
email
search our site
  
FDA-RELATED NEWS
 
 
 
TXT FDA Seeking to Improve Hiring Process for New Staff
11/15/2017
 
 
TXT Leave Battlefield Medical Decisions to FDA: Senate Vote
11/16/2017
 
 
TXT Rep. DeLauro Seeks Ban on DTC Ads, Again
11/17/2017
 
 
TXT CGMP Violations Found in 2 Lupin Facilities
11/14/2017
 
 
TXT Issues Found in TV Ad ‘Major Statements’: Study
11/14/2017
 
 
TXT Direct Device Marking Guidance
11/16/2017
 
 
TXT Pull Benicar from Market: Public Citizen
11/15/2017
 
 
TXT Progress and Some Concerns in NARMS Report
11/15/2017
 
 
TXT Companies Making Cybersecurity Progress: Schwartz
11/14/2017
 
 
TXT Multiple Violations Found at RTI Surgical
11/14/2017
 
 
TXT Latest Federal Register Notices
11/19/2017
 
 
TXT Since Our Last Issue ...
11/19/2017
 
 
TXT Product Approval Summaries
11/19/2017
 
 
TXT FDA Panel Votes Down Bayer’s Ciprofloxacin for Bronchiectasis
11/17/2017
 
 
TXT Gottlieb Steps in to Ease Hospital Product Shortages
11/17/2017
 
 
TXT FDA on Schedule with Sunscreen Innovation Act: GAO
11/16/2017
 
 
TXT Former CDER Product Quality Director Joins Parexel
11/16/2017
 
 
TXT FTC Finalizes Abbott/Alere Acquisition Consent Order
11/15/2017
 
 
TXT Acorda Phase 3 Parkinson’s Study Sees 5 Deaths
11/15/2017
 
 
TXT Draft Guidance on Biosimilar User Fees
11/15/2017
 
 
TXT Safety Alert on Silicone Marketed as Body Contouring Product
11/14/2017
 
 
TXT Latest FDA Warning Letters
11/14/2017
 
 
TXT Ways to Improve FDA Unapproved Drugs Initiative
11/14/2017
 
 
TXT Pharmacy Owner Pleads Guilty in $100 Million Compounding Fraud
11/13/2017
 
 
 
 
The most authoritative FDA news analysis each week is found in the pages of Dickinson's FDA Review. Since 1984, this newsletter has been providing in-depth reports on the most significant FDA developments affecting the pharmaceutical, medical device, biologics and veterinary medicines industries. Unlike other media, FDA Review eliminates time-wasting minutia and presents in clear, concise language the essence of what's really important - and why. It is the publication that FDA officials themselves read. Delivered in the middle of each week, FDA Review presents:
  • The latest agency policy developments, often before they're officially announced;
  • Major news insights, follow-ups and reactions in each product area;
  • Summaries of the latest Warning Letters;
  • The newest product approvals;
  • Summaries of the latest FDA Federal Register notices;
  • Summaries of DDMAC letters;
  • Related industry news capsules;
  • The industry's most concise FDA news index;
  • Inside-FDA news briefs
You can rely on FDA Review to provide only what's important - in the most convenient and time-saving